Clinical trials: Neuroglioblastoma

Multiple Myeloma, Diffuse Large B-Cell Lymphoma (DLBCL)

Karyopharm Expanded Access Program for Selinexor

• Available
• Age: All ages
• Expanded access

KEAP is an expanded access program designed to provide selinexor to eligible participants outside of a clinical trial before the drug has been given marketing approval by the country's regulatory agency or the drug is…

Conditions

Multiple Myeloma, Diffuse Large B-Cell Lymphoma (DLBCL), Sarcoma, Neuroglioblastoma

Trial name

KEAP (NCT07215832)

Testing

selinexor

Sponsor

Karyopharm Therapeutics Inc